Sanofi (ENXTPA:SAN) has expanded its rare disease collaboration with Mirecule, focusing on next generation treatments for ...
After 30 months of fast-paced innovation in quantum algorithms, six research groups are hoping to hit paydirt. But there can ...
Dyne Therapeutics (NASDAQ:DYN) executives outlined a slate of 2026 operational and regulatory milestones during a discussion ...
Tech Xplore on MSN
Simple motor networks mimic human muscle behavior under increasing load
Scientists have developed a network of mechanical motors that mimic the molecular machinery underpinning human muscle ...
Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified sub ...
Living with a rare disease often means years of uncertainty, misdiagnosis, and limited treatment options. But advances in ...
Sarepta Therapeutics receives a revised brokerage price outlook, drawing market attention toward the rare disease biotechnology segment. Institutional capital repositioning across biotechnology ...
As Congress mulls whether to follow President Donald Trump’s orders for a most-favored-nation drug-pricing policy, biotech ...
The Food and Drug Administration's vaccine chief will leave the agency next month, marking the second time he has stepped down from the role since his appointme ...
BioCatch, which prevents fraud and financial crime by recognizing patterns in human behavior, today announced the launch of ...
Scientists have developed a network of mechanical motors that mimic the molecular machinery underpinning human muscle ...
Learn more about whether Revvity, Inc. or 10x Genomics, Inc. is a better investment based on AAII's A+ Investor grades, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results